New drug tested for rare bleeding disorder
NCT ID NCT07347249
Summary
This study is testing a single dose of an experimental drug called sutacimig in adults with severe congenital Factor VII deficiency, a rare bleeding disorder. The main goals are to check if the drug is safe and to see how the body processes it. Researchers will also measure if it helps improve blood clotting in participants with a history of serious bleeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL FACTOR VII DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal London Hospital
RECRUITINGLondon, E1 2ES, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.